chrisvoncsefalvay/vaers-outcomes huggingface dataset:
"31JUL97 7AM pt awoke got in parents bed (usually up @ 9AM) 9AM mom tried to arouse but unable, so let sleep till 11:00 awakened child placed on sofa, very pale, slumped over & slept;to ER- took fluids;"
Pregnant patient; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnant patient) in a 30-year-old female patient (gravida 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     No medical history was reported.  Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for an unknown indication.    On 18-Mar-2021 at 10:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 21-Sep-2020 and the estimated date of delivery was 28-Jun-2021. On 18-Mar-2021, the patient experienced EXPOSURE DURING PREGNANCY (Pregnant patient). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-fifth week of the pregnancy. The delivery occurred on an unknown date, which was reported as Unknown. For neonate 1, The outcome was reported as Unknown. At the time of the report, EXPOSURE DURING PREGNANCY (Pregnant patient) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 25-Oct-2020, Pregnancy test: other (Positive) Positive. On an unknown date, Prenatal screening test: unknown (Inconclusive) Unknown. On an unknown date, Ultrasound scan: unknown (Inconclusive) Unknown.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medications were provided.
Developed lt upper arm pain and swelling on1/26/14. Lt upper arm rash 1/28/14. Maculopapular rash to abdomen and chest 1/29/14. 1/31/14 states abd rash resolved, chest lesions crusted over lt arm improving.
3/24-25/2001Extreme Achy, nauseated, head ache for 1.5 days. 3/24 Missed day of work. In bed for 21 hours.  3/25 Headache when bending over following days  3/26 light headache
Administered SARS-COV-2 (COVID) 2023-24 (6MO-11YR)(MODERNA), MRNA. The manufacture provided 0.5mL per vial instead of 0.25mL per vial.
rash on buttocks and back of legs, happened the next day but went away by the following morning
Developed Erythema nodosum rash on the legs, with joint pain leading to back pain.
Developed (B) knee & ankle pain, abdominal rash 2 wks after MMR. Above symptoms cleared after 3 days
7/10/02 began having bruising and petechia. Platelet count was 600 that night. Pt was given IV platelet count was 12,000 after infusion. Bone marrow biopsy was normal. 7/12/02 count was 40,000. 7/15 count was normal. Pt did have nasal congestion on 7/8/02.  Nurse follow up on 07/20/04 states: "Idiopathic Thrombocytopenia  Purpura."
high fever, chills, shaking, severe headache, body aches, joint pain; all symptoms started roughly 7 hours after the injection, peaked roughly 14 hours after the injection, and have since receded to some physical soreness and a mild headache, 2 days after the injection
severe headache (borderline migraine level) overnight, subsided over the course of the next morning.
Patient returned for 2nd dose on 3/26/2021, at that time, she reported to nurse that she was hospitalized at a Medical Center around 9-10 days after first dose of vaccine due to a pulmonary embolism. Attempts made to the hospital to obtain records but did not receive any.
PATIENT REPORTED SHE HAS SWOLLEN EYES, HEADACHE AND CHILLS AFTER GETTING AREXVY AND COMIRNATY THE DAY BEFORE. SHE DID NOT REMEMBER HAVING ANY BAD SIDE EFFECTS WITH THE PFIZER VACCINES BEFORE SO IT  IS POSSIBLE THAT SHE HAD AN ALLERGIC REACTION TO THE RSV VACCINE (AREXVY). PATIENT DID NOT HAVE TROUBLE BREATHING SO WAS ADVISED TO TAKE BENADRYL AND WAIT IT OUT AND SEE IF SHE DID NOT GET BETTER THEN SHE'D NEED TO GO TO  THE ER.
bump on tip of tongue.  unsure of it was there before.  no numb, no tingle, no angioedema, no sob, no stridor. no acute distress.  declined further assistance and ER.
8:30 started w/high pitched cry for 30 mins; given APAP; 9PM on arrival home crying stopped but appeared very pale, limp but awake; no fever; teeth chattering, given warm bath & put to bed; 10MAR temp as high as 100.6;
Day 8 after receiving Moderna COVID-19 vaccine, experienced mild rash on arm at injection site. Also felt mild heat and itchiness. AE continued for 3 days before resolving.
Information has been received from a licensed practical nurse (L.P.N.) concerning a 16 year old female who was vaccinated with GARDASIL, intramuscularly. Subsequently the patient fainted. The patient recovered on an unspecified date. This is one of two reported from the same source. Additional information has been requested. This is in follow-up to report (s) previously submitted on 12/14/2007.  Information has been received from a licensed practical nurse (L.P.N.) concerning a 16 year old female who was vaccinated with GARDASIL, intramuscularly.  Subsequently the patient fainted.  The patient recovered on an unspecified date.  This is one of two patients reported from the same source.  Additional information has been requested.  Additional information from the nurse on 11-DEC-2007 indicated she was unable to identify the patients involved.
Dizziness, fell x 2 on knees. Patient was anxious, no breakfast. Given water, juice, graham crackers. Final BP 92/62.
This spontaneous report was received from a nurse via Pfizer refers to a patient of unknown demographics. The patient's relevant medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23, single dose vial (strength, lot number, expiry date was not provided) for prophylaxis (incorrect product storage).
This case was reported by a other health professional via call center representative and described the occurrence of fever in a 61-year-old female patient who received FLUARIX QUADRIVALENT. On 21st October 2015, the patient received FLUARIX QUADRIVALENT .5 ml. In October 2015, less than a month after receiving FLUARIX QUADRIVALENT, the patient experienced platelet count low, spleen enlarged, liver enlargement, hemoglobin decreased, elevated liver enzymes and hepatitis C test positive. On 23 October 2015, the patient experienced fever. The patient was treated with TYLENOL. On an unknown date, the outcome of the fever, platelet count low, spleen enlarged, liver enlargement, hemoglobin decreased, elevated liver enzymes and hepatitis C test positive were recovering/resolving. The reporter considered the fever, platelet count low, spleen enlarged, hemoglobin decreased, elevated liver enzymes and hepatitis C test positive to be probably related to FLUARIX QUADRIVALENT. It as unknown if the reporter considered the liver enlargement to be related to FLUARIX QUADRIVALENT. Additional details provided were as follows: This case was reported by a certified medical assistant, who herself was the patient. This case was previously reported to a doctor. On 21st October 2015, at 05:00, the patient received a dose of FLUARIX QUADRIVALENT vaccine in left deltoid. On 23rd October 2015, at 05:00, 2 days after vaccination, the patient developed fever (101.5 degrees F). The patient took TYLENOL. The fever continued for the next 3 days. On 27th October 2015, at 12:00 noon, the fever was (102.5 degrees F). There were no other external symptoms present. On the same day, the patient had blood drawn and underwent laboratory tests, which showed high liver functions and an abnormal blood count. All inflammatory marker tests showed elevations. The patient tested positive for Hepatitis C. On 28th October 2015, the patient underwent an abdominal ultrasound, which revealed an enlarged liver and spleen. The spleen was dangerously enlarged. Over the next week, the patient underwent blood work, which showed liver functions kept rising. The Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and Alkaline Phosphatase tests showed elevations. Two days later test result came back, that the patient did not have Hepatitis C. Her hemoglobin levels decreased from 12.5 to 9.7. The patient stressed that, she was normally a very healthy individual. The patient again underwent a 2nd set of Hepatitis C titers 2 weeks after the initial lab work and results came back negative. The patient added that a month before the vaccination, she had routine blood work done and all levels were good. The patient was scheduled for laboratory work in coming week and said she would have results that she can share when she receives the follow up form.
Approximately 20 minutes after receiving vaccination, patient reported dizziness and blurred vision. Patient almost fell while walking and was sat down. Patient was clammy and diaphoretic and blood pressure was elevated from her normal but O2 was normal. No swelling but patient reported drainage in her throat, a thick mucus like feeling. Ambulance was called and patient was taken away on stretcher, was not able to stand to get on stretcher.
Pfizer BioNTech COVID-19 Vaccine EUA: COVID-19 case resulting in Hospitalization / Death. Patient received Pfizer Vaccines on 4/7/2021 and 4/30/2021. Presented to ED on 8/17/2021 with cough, nausea, vomiting, diarrhea fever of 102, loss of appetite, and decreased UOP. Treated initially for DKA, and placed on HFNC. DKA resolved, and transitioned off insulin gtt 8/21. Due to increasing oxygen requirements, patient intubated on 8/23, and subsequently required proning. Developed septic shock, requiring norepinephrine and vasopressin gtt. Worsening renal function prompted Vascath placement and initiation of dialysis 8/29. Patient continued to deteriorate clinically, requiring the addition of epinephrine for blood pressure support, and worsening respiratory acidosis and hypoxemia. He developed wide complex tachycardia requiring 1 shock, after which family was called for goals of care discussion. Transitioned patient to comfort care, and he expired shortly thereafter.
Patient felt dizzy and fainted. She ended up having to vomit and felt fine afterwards.
Patient experience pain at injection site. Patient eventually went to the ER. X-ray was taken and she was given some pain medication in the ER.
Metallic taste and tingling in left side of mouth and tongue started minutes after vaccine administration. It?s now 9:52 PM and I still have same taste feeling.
had 99 degree fever; Nerve pain; Arm hurt/Arm a little sore; fatigue/tired; Muscle aches; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 56 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administration date 09Oct2021 (Batch/Lot number: unknown) at the age of 56 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "obesity factor" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose Number: 1), for COVID-19 immunization, reaction(s): "little tired"; Bnt162b2 (Dose Number: 2), for COVID-19 immunization, reaction(s): "little tired".  The following information was reported: NEURALGIA (non-serious) with onset 09Oct2021, outcome "recovered" (10Oct2021), described as "Nerve pain"; PAIN IN EXTREMITY (non-serious) with onset 09Oct2021, outcome "unknown", described as "Arm hurt/Arm a little sore"; FATIGUE (non-serious) with onset 09Oct2021, outcome "unknown", described as "fatigue/tired"; MYALGIA (non-serious) with onset 09Oct2021, outcome "recovered" (10Oct2021), described as "Muscle aches"; PYREXIA (non-serious) with onset 11Oct2021, outcome "unknown", described as "had 99 degree fever". Therapeutic measures were not taken as a result of neuralgia, pain in extremity, fatigue, myalgia, pyrexia.  Additional Information: When given needle, felt like it hit a nerve.  Felt nerve pain at temple all day Oct 9.  Nerve pain was gone Oct 10. Arm hurt Oct 9-10 Extreme fatigue Oct 9 in evening and Oct 10 Muscle aches everywhere Oct 9-10. Felt fine Oct 11 during the day but had 99 degree fever, muscle aches, and tired in the evening Arm a little sore. No reaction to Shots 1 and 2 except a little tired. Patient was not diagnosed with covid-19 Prior to vaccination, It was unknown if patient received other vaccine in four weeks.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Severe flu like symptoms (sore throat, fatigue, feeling like being hit by a truck) Per pt, seems to be getting better throughout the day.
5 days later had a severe cold, bad cough, fever p/which 10 dasy had to go to MD for ATB & cough syrup;
I had only pain at the injection site after the first dose on February 12. I got my second dose on Friday, March 12 at 1pm and woke up at 2am Saturday  with debilitating headache and severe nausea . I took tylenol and fell back asleep. I woke up again around 6am with the same severe headache and excruciating  pain in my left arm at the injection site and tried to get up to get some ibuprofen. I felt extremely dizzy and could barely walk which ended up in me fainting in the kitchen. I somehow got back to bed, took ibuprofen and went back to sleep. I started feeling better after that, severe headache went away but I had low grade fever, chills, slight nausea and painful arm the whole Saturday up until Sunday morning. I had dizziness on Sunday, was very tired on Monday and still felt weak on Tuesday but after that I recovered and experienced no more symptoms.
Dyskinesia for about 2 hours, with involuntary head, arm, leg movements
Light-headedness and nausea, mostly with position changes or walking, lasting up to 2 hrs, relieved with lying down, for 3 days, beginning 4 days after receiving 3rd Gardasil vaccine.  Had 2 episodes 1st day, then 4 episodes next day. Came in for eval 3rd day, had brief episode that morning, and for 2 min. while standing in office.  Menses started 2nd day.  Also some difficulty falling asleep 1st and 2nd days.  Symptoms all resolved by 4th day, was reportedly back to normal.   No treatment given except recommendation to increase fluids, get up slowly.
Muscle weakness, nerve damage, burning in legs, numbness/tingling in legs, numbness/tingling feet and hands and arms, severe cramping - cannot walk for more than a few minutes.    Treatment will involve Solumedrol steroid injections, Tizanidine muscle relaxers, and Meloxicam inflammatory medication.
Itching, redness, lumpiness underneath skin, uneven swelling, (hills and valleys), bumps 3 inches below inject site. Hot to touch, soreness. Iced area but although redness decreased, area affected expanded. Also had nausea, headache and breathing problems, stuffy nose. After hours nurse recommended Tylenol, By midnight breathing problems had worsened and other doctor recommended Allegra which was helpful. ON 08/04 went to doctor, continued to ice area, was seen by OBGYN since a surgery was planned, allergist, and general practitioner who took pictures. On 8/05 continued on Allegra twice daily, breathing fine, swelling down but redness still present and increases.
hives and Urticaria at the injection site; Dermatographia on his chest and arms; This case was reported by a other health professional via call center representative and described the occurrence of injection site hives in a 12-year-old male patient who received Flu Seasonal QIV Quebec (FluLaval Tetra 2019-2020 season) (batch number 59KC5, expiry date 11th June 2020) for prophylaxis.   On 24th October 2019, the patient received FluLaval Tetra 2019-2020 season .5 ml. On 25th October 2019, 1 days after receiving FluLaval Tetra 2019-2020 season, the patient experienced injection site hives and dermatographia. The patient was treated with benadryl (nos) (Benadryl). On an unknown date, the outcome of the injection site hives and dermatographia were resolved with sequelae.   It was unknown if the reporter considered the injection site hives and dermatographia to be related to FluLaval Tetra 2019-2020 season.  Additional details were provided as follows: The reporter stated that the patient after vaccination experienced hives and Urticaria at the injection site and Dermatographia on his chest and arms. The reporter stated that the patient was given benadryl during the day at school on 25th October 2019 and then again that evening. The reporter consented to follow up.
Upper right and left back pain when laying down or trying to sleep; On going muscle and joint pain; Upper right and left back pain when laying down or trying to sleep; On going muscle and joint pain; This is a spontaneous report from a Contactable Consumer. The reporter is the patient.  A 54 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 30Sep2021 11:00 (Batch/Lot number: unknown) at the age of 54 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "sleep apnea" (unspecified if ongoing), notes: sleep apnea; "blood pressure" (unspecified if ongoing), notes: blood pressure. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Prev dose brand=pfizer, Prev dose brand unknown=False, Prev dose lot number=301358A, Prev dose lot unknown=False, Prev dose administration date=30Sep2021, Prev dose dose number=1), for COVID-19 immunization. The following information was reported: BACK PAIN (non-serious), PAIN IN EXTREMITY (non-serious) all with onset 11Oct2021 12:00, outcome "not recovered" and all described as "Upper right and left back pain when laying down or trying to sleep"; ARTHRALGIA (non-serious), MYALGIA (non-serious) all with onset 11Oct2021 12:00, outcome "not recovered" and all described as "On going muscle and joint pain". The events "upper right and left back pain when laying down or trying to sleep", "on going muscle and joint pain", "upper right and left back pain when laying down or trying to sleep" and "on going muscle and joint pain" were evaluated at the physician office visit. It was unknown if therapeutic measures were taken as a result of back pain, arthralgia, pain in extremity, myalgia.  Additional information: Patient did not received other vaccine within four weeks of Covid vaccine. Patient did not experience Covid prior to vaccination, patient did not test positive post vaccination.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
The next day I woke up and one eye was swollen.  Since then my eyes are almost always swollen.  Some days more than others and it different eyes are swollen on different days.  Timing doesn't coincide with allergy season, illnesses or periods.  Acne in the area seems to make it worse but does not seem to be the cause.
Missed second dose; tested positive for pregnancy; Small headache; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Missed second dose), EXPOSURE DURING PREGNANCY (tested positive for pregnancy) and HEADACHE (Small headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On 20-May-2021, the patient experienced HEADACHE (Small headache). On 08-Jun-2021, the patient experienced EXPOSURE DURING PREGNANCY (tested positive for pregnancy). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed second dose). The patient was treated with NAPROXEN SODIUM (ALEVE) at an unspecified dose and frequency. On 25-May-2021, HEADACHE (Small headache) had resolved. On 08-Jun-2021, EXPOSURE DURING PREGNANCY (tested positive for pregnancy) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (Missed second dose) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-Jun-2021, Pregnancy test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported.
joint pain; pain at injection site; This case was reported by a consumer via call center representative and described the occurrence of joint pain in a 76-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concomitant products included ibuprofen.   On 11th September 2019, the patient received the 1st dose of Shingrix (intramuscular). On 11th September 2019, less than a day after receiving Shingrix, the patient experienced joint pain and injection site pain. On an unknown date, the outcome of the joint pain and injection site pain were recovering/resolving.   It was unknown if the reporter considered the joint pain and injection site pain to be related to Shingrix.  Additional details were received as follows: The patient experienced joint pain and pain at the injection site. The patient planned to continue follow-up with her physician on an unknown date. The patient consented to follow up. This case has been linked to US2019AMR223692, reported by the same reporter.
Rash covering body flared up eczema irratibilty fatigue refusal to eat.
I got the vaccine yesterday and today my site is swollen and deep red in color; I got the vaccine yesterday and today my site is swollen and deep red in color; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (I got the vaccine yesterday and today my site is swollen and deep red in color) and VACCINATION SITE ERYTHEMA (I got the vaccine yesterday and today my site is swollen and deep red in color) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE SWELLING (I got the vaccine yesterday and today my site is swollen and deep red in color) and VACCINATION SITE ERYTHEMA (I got the vaccine yesterday and today my site is swollen and deep red in color). At the time of the report, VACCINATION SITE SWELLING (I got the vaccine yesterday and today my site is swollen and deep red in color) and VACCINATION SITE ERYTHEMA (I got the vaccine yesterday and today my site is swollen and deep red in color) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       I got the vaccine yesterday and today my site is swollen and deep red in color is this normal.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
This case was reported by a nurse via call center representative and described the occurrence of general body pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis. The patient's past medical history included migraine. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced general body pain. On an unknown date, the outcome of the general body pain was recovered/resolved. It was unknown if the reporter considered the general body pain to be related to Shingrix. Additional details provided as follows: This case was reported by the patient who herself was a nurse. The age at vaccination was not reported however it could be 59 or 60. The patient received first dose of Shingrix and experienced body aches that lasted for 2 days. For tolerance to 2nd dose, refer case US2019045285